Compare Keysight Technologies Inc (KEYS) vs Kymera Therapeutics Inc. Common Stock (KYMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keysight Technologies Inc vs Kymera Therapeutics Inc. Common Stock — how do they compare? Keysight Technologies Inc trades at $352.53 (market cap $63.03B), while Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B). The key difference: Keysight Technologies Inc is far larger — about 7.1× Kymera Therapeutics Inc. Common Stock's market cap, and Keysight Technologies Inc is trading nearer its 52-week high, Kymera Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Keysight Technologies Inc for 57 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| KEYS | KYMR | |
|---|---|---|
Market Cap | $63.03B | $8.87B |
Volume | 1,168,526 | 779,107 |
Sector | Technology | Health |
52-Week High | $387.90 | $127.31 |
52-Week Low | $162.19 | $55.80 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | $63.17B | $8.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keysight Technologies (KEYS) trades at $357.59, down 5.32% over 24 hours, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.07 exceeding expectations. Revenue for 2025 reached $5.38 billion, with a net income margin of 15.81%. Recent news highlights growth in AI infrastructure and 6G testing solutions.
The outlook remains positive with a consensus price target of $421.29, implying significant upside. Risks include elevated valuation multiples and supply constraints affecting near-term revenue conversion. Institutional sentiment is bullish, with 81% of analysts rating the stock a buy.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →
